Articlenpj drug discovery2025
Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trial.
Article in npj drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intranasal monoclonal antibodies (mAbs) offer a promising cost-reducing and non-invasive alternative to systemic administration. Intranasal palivizumab prevented respiratory syncytial virus (RSV) infection in mice but not in healthy infants. This proof-of-concept study evaluates the efficacy of intranasal palivizumab to prevent RSV infection. In this randomized, double-blind, placebo-controlled, experimental infection model, 28 healthy adults (18-55 years old) were randomized 1:1 to receive 1 mg/mL palivizumab in saline nasal drops or placebo one hour prior to RSV-A Memphis 37b challenge (EU clinical trial register 2020-004137-21, August 14, 2021). The primary outcome was viral load over time, determined by RT-qPCR. Intranasal palivizumab had no effect on viral load despite a 72% reduction in symptomatic infections and marginally reduced upper respiratory tract symptoms compared to placebo. Intranasal palivizumab does not protect against RSV infection under optimally controlled conditions. Intranasal mAbs are highly unlikely to be a feasible and cost-effective method of protection against respiratory infection.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.